As a note, this decreased activity of the native T cell repertoire in response to self-antigens is likely why vaccination against cancer testis antigens NY-ESO-1 or MAGE-A3 is well tolerated, while infusion of ex-vivo engineered TCR T cells targeting these same antigens led to significant alloreactivity and toxicity, as discussed above. The gene discussed is MAGEA3; the disease is cancer.